STOK
Income statement / Annual
Last year (2023), Stoke Therapeutics, Inc.'s total revenue was $8.78 M,
a decrease of 29.22% from the previous year.
In 2023, Stoke Therapeutics, Inc.'s net income was -$104.70 M.
See Stoke Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$8.78 M
|
$12.41 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.73 M |
$3.54 M |
$2.23 M |
$1.93 M |
$450,000.00 |
$214,000.00 |
$113,000.00 |
| Gross Profit |
$4.05 M |
$8.87 M |
-$2.23 M |
-$1.93 M |
-$450,000.00 |
-$214,000.00 |
-$113,000.00 |
| Gross Profit Ratio |
0.46 |
0.72 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$79.76 M
|
$77.84 M
|
$54.17 M
|
$32.20 M
|
$23.76 M
|
$8.37 M
|
$3.60 M
|
| General & Administrative
Expenses |
$41.32 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$11.91 M
|
$4.41 M
|
$1.96 M
|
| Selling & Marketing
Expenses |
-$2.26 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$39.06 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$11.91 M
|
$4.41 M
|
$1.96 M
|
| Other Expenses |
$166,000.00 |
$167,000.00 |
$140,000.00 |
$57,000.00 |
$2,000.00 |
-$10,000.00 |
-$4,000.00 |
| Operating Expenses |
$118.82 M |
$116.76 M |
$86.07 M |
$53.04 M |
$35.68 M |
$12.78 M |
$5.55 M |
| Cost And Expenses |
$123.55 M |
$116.76 M |
$86.07 M |
$53.04 M |
$35.68 M |
$12.78 M |
$5.55 M |
| Interest Income |
$0.00 |
$3.12 M |
$120,000.00 |
$744,000.00 |
$3.35 M |
$270,000.00 |
$0.00 |
| Interest Expense |
$9.91 M |
$3.12 M |
$120,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$4.73 M
|
$3.54 M
|
$2.23 M
|
$1.93 M
|
$450,000.00
|
$214,000.00
|
$113,000.00
|
| EBITDA |
-$110.04 M
|
-$104.36 M
|
-$86.07 M
|
-$53.04 M
|
-$35.68 M
|
-$12.57 M
|
-$5.44 M
|
| EBITDA Ratio |
-12.53 |
-8.41 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-13.07
|
-8.41
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$10.07 M
|
$3.29 M
|
$260,000.00
|
$801,000.00
|
$3.35 M
|
-$10,000.00
|
-$4,000.00
|
| Income Before Tax |
-$104.70 M |
-$101.07 M |
-$85.81 M |
-$52.24 M |
-$32.33 M |
-$12.52 M |
-$5.56 M |
| Income Before Tax Ratio
|
-11.92
|
-8.15
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$4.56 M |
-$7.96 M |
-$1.09 M |
-$1.63 M |
-$3.80 M |
$260,000.00 |
$0.00 |
| Net Income |
-$104.70 M |
-$93.11 M |
-$84.71 M |
-$50.61 M |
-$28.52 M |
-$12.52 M |
-$5.56 M |
| Net Income Ratio |
-11.92 |
-7.51 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.38 |
-2.39 |
-2.31 |
-1.51 |
-1.59 |
-0.53 |
-0.43 |
| EPS Diluted |
-2.38 |
-2.39 |
-2.31 |
-1.51 |
-1.59 |
-0.53 |
-0.43 |
| Weighted Average Shares
Out |
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$12.79 M
|
| Weighted Average Shares
Out Diluted |
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$12.79 M
|
| Link |
|
|
|
|
|
|
|
